Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093242 | 0.76 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CBPIK3CGNPC1 | |
| SCHEMBL24023268 | 0.76 | MEN1 (0.33) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL24023248 | 0.75 | MAPK14 (0.37) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL24023338 | 0.73 | XIAP (0.34) | NPC1RAB9AKMT2AMEN1CASP3 | |
| SCHEMBL24023331 | 0.72 | ALDH1A1 (0.36) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL3086729 | 0.72 | ALDH1A1 (0.36) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL2327834 | 0.72 | PIK3CD (0.62) | PIK3CDPIK3CAPIK3CBPIK3CGMAPT | |
| SCHEMBL14302479 | 0.72 | SMN1; SMN2 (0.36) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL24023335 | 0.71 | PIK3CA (0.41) | PIK3CDPIK3CAPIK3CBPIK3CGMAPT | |
| SCHEMBL2958703 | 0.70 | PIK3CD (0.59) | PIK3CDPIK3CAPIK3CBPIK3CGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799810-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799810-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799810-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7754746-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7754746-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-20100120865-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100120865-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100120865-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| EP-2035413-A2 | THIAZOLYL UREA DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | Novartis AG (CH) | 2009-03-18 | — | — | EP | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| WO-2008000421-A2 | THIAZOLYL UREA DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008000421-A2 | THIAZOLYL UREA DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007068473-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120865-A1 | Organic compounds | PIK3C3, PIK3R3, PIK3R4 | PIK3CD 10/4885PIK3CA 5/4885PIK3CB 11/4885 |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | AKT3, PIK3R3, PIK3CD | PIK3CD 3/4885PIK3CA 4/4885PIK3CB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.